STOCK TITAN

Alkermes plc - ALKS STOCK NEWS

Welcome to our dedicated news page for Alkermes plc (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alkermes plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alkermes plc's position in the market.

Rhea-AI Summary
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
none
-
Rhea-AI Summary
Alkermes reports strong Q2 2023 financial results with revenues of $617.4 million and net sales of proprietary products increasing by 21% YoY. The company recorded $248.4 million in back royalties and interest from the Janssen arbitration. GAAP net income was $237.1 million, and non-GAAP net income was $94.3 million. Financial expectations for full-year 2023 reiterated. Alkermes continues progress on planned separation of oncology business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.56%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
conferences earnings
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.07%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
none
-
Rhea-AI Summary
Independent proxy advisory firm ISS recommends shareholders support Sarah Schlesinger for the board of Alkermes plc. They advise withholding support from cancer specialist Richard Gaynor due to an upcoming oncology spin. Sarissa Capital Management issues a presentation advocating for shareholder representation. Shareholders are urged to vote in favor of Sarissa Nominees and against executive compensation. Contact D.F. King & Co., Inc. for assistance with voting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
none
-
Rhea-AI Summary
Alkermes' seven independent directors issue a letter to shareholders ahead of the upcoming Annual General Meeting, recommending that shareholders vote 'FOR' the director nominees. The directors highlight their achievements and the company's strong performance, including a 49% increase in share price since the announcement of the Value Enhancement Plan. They emphasize the strategic priorities for driving value, such as the successful launch of LYBALVI® and the planned separation of the oncology business. The directors express disagreement with ISS's recommendation to vote against Dr. Gaynor's re-election.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none
Alkermes plc

Nasdaq:ALKS

ALKS Rankings

ALKS Stock Data

4.02B
158.79M
1.25%
108.01%
8.58%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Ireland
Dublin

About ALKS

alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.